2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
3
Breast Neoplasms
3
Weight Loss
2
Polyps
2
Hyperplasia
2
Stomach Neoplasms
1
Psoriasis
1
Osteoarthritis
1
Neoplasms
1
Muscular Atrophy
1
Muscle Weakness
1
Motor Activity
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Chronic-Phase
1
Colitis, Ulcerative
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Cancer Cachexia
1
Cachexia
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Anorexia
1
Adenomatous Polyps
1
Adenomatous Polyposis Coli
1
Interventions
telitacicept
3
fludarabine
3
Prednisone
3
Data Collection
3
Cyclophosphamide
3
Specimen Handling
2
Nivolumab
2
Blood Specimen Collection
2
Antilymphocyte Serum
2
thymoglobulin
1
remdesivir
1
prednylidene
1
human papillomavirus vaccine, L1 type 16, 18
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
cabozantinib
1
apremilast
1
Watchful Waiting
1
Vitamin D
1
Valsartan
1
Telemedicine
1
Surveys and Questionnaires
1
Standard of Care
1
Pyridostigmine Bromide
1
Practice Guidelines as Topic
1
Population Groups
1
Platinum Compounds
1
Plasma Exchange
1
Phlebotomy
1
Peripheral Blood Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Autoimmune Diseases
×
Eicosapentaenoic Acid
×
Clear all
NCT01351805
2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA
Completed
25,871 enrolled
15 charts